Trial Profile
Randomized Clinical Comparison of Everolimus-Eluting SYNERGY and Biolimus-Eluting BioMatrix NeoFlex Coronary Stents in Non-Selected Patients With Ischemic Heart Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms SORT-OUT VIII
- 06 Jun 2019 Results of a pre-specified sub-study assessing 12-month clinical outcomes in patients with and without diabetes treated with EES or BES, published in the American Journal of Cardiology
- 25 Sep 2018 Results of the secondary endpoints at 1-year follow-up are not available yet, but will be presented at TCT as per results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 25 Sep 2018 Results of SORT OUT VIII substudy reporting the outcomes of stents in patients with and without diabetes presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics